-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 BS5JvMpdkC/kiNNdRYv0Ixb7UQ3dKBxlHvSgDCF1ytnA8l8GeioCQ8yWmk8jf4Co
 p+ZMtpVD5jhQlwJWnrdV+g==

<SEC-DOCUMENT>0001178913-08-001057.txt : 20080429
<SEC-HEADER>0001178913-08-001057.hdr.sgml : 20080429
<ACCEPTANCE-DATETIME>20080429080827
ACCESSION NUMBER:		0001178913-08-001057
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20080429
FILED AS OF DATE:		20080429
DATE AS OF CHANGE:		20080429

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			COMPUGEN LTD
		CENTRAL INDEX KEY:			0001119774
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-30902
		FILM NUMBER:		08783090

	BUSINESS ADDRESS:	
		STREET 1:		72 PINCHAS ROSEN ST
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			69512
		BUSINESS PHONE:		011-972-3-765-8585

	MAIL ADDRESS:	
		STREET 1:		72 PINCHAS ROSEN ST
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			69512
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>zk85158.htm
<TEXT>
<HTML>
<HEAD>
     <!-- Created by EDGAR Ease Plus (EDGAR Ease+) -->
     <!-- Project:        F:\EDGAR Filing\Compugen Ltd\85158\a85158.eep                    -->
     <!-- Control Number: 85158                                                            -->
     <!-- Rev Number:     1                                                                -->
     <!-- Client Name:    Compugen Ltd                                                     -->
     <!-- Project Name:   6-K                                                              -->
     <!-- Firm Name:      Zadok-Keinan Ltd                                                 -->
     <TITLE>6-K</TITLE>
</HEAD>
<BODY>
<!-- MARKER FORMAT-SHEET="Scotch Rule Top-TNR" FSL="Workstation" -->
<HR ALIGN=LEFT WIDTH=100% SIZE=4 NOSHADE STYLE="margin-top: -5px">
<HR ALIGN=LEFT WIDTH=100% SIZE=1 NOSHADE STYLE="margin-top: -10px">




<!-- MARKER FORMAT-SHEET="Head Major Center Bold-TNR" FSL="Workstation" -->
<H1 ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=4>FORM 6-K <BR>SECURITIES AND
EXCHANGE COMMISSION </FONT></H1>

<!-- MARKER FORMAT-SHEET="Head Major Center Bold 1-TNR" FSL="Workstation" -->
<H1 ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Washington, D.C. 20549 </FONT></H1>

<!-- MARKER FORMAT-SHEET="Head Major Center Bold 1-TNR" FSL="Workstation" -->
<H1 ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Report of Foreign
Private Issuer </FONT></H1>

<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Workstation" -->
<P ALIGN="Center"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Pursuant to rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934<BR> for the month of April 2008  </FONT></P>

<!-- MARKER FORMAT-SHEET="Head Center Underline-TNR" FSL="Workstation" -->
<P ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE="5"><U><B>Compugen Ltd.</B></U> </FONT><BR><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(Translation of
registrant&#146;s name in English) </FONT></P>

<!-- MARKER FORMAT-SHEET="Head Center Underline-TNR" FSL="Workstation" -->
<P ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2><U>72 Pinchas Rosen
Street, Tel-Aviv 69512, Israel</U><BR>(Address of principal
executive offices) </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Workstation" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Indicate by check mark whether the
registrant files or will file annual reports under cover Form 20-F or Form 40-F. </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Workstation" -->
<P ALIGN="Center"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Form 20-F <FONT size="3" face="Wingdings">x
</font>  Form 40-F  <FONT size="3" face="Wingdings">o
</font></FONT></P>

<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Workstation" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>On April 29, 2008 Compugen Ltd. (the &#147;Registrant&#148;)
issued a Press Release, filed as Exhibit 1 to this Report on Form 6-K, which is hereby
incorporated by reference herein. </FONT></P>

<!-- MARKER FORMAT-SHEET="Head Major Center Bold-TNR" FSL="Workstation" -->
<H1 ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><U>SIGNATURE</U> </FONT> </H1>

<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Pursuant to the requirements of the
Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed
on its behalf by the undersigned, thereunto duly authorized. </FONT></P>


<!-- MARKER FORMAT-SHEET="Signature (Single)" FSL="Workstation" -->
<TABLE WIDTH=100% CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR VALIGN=TOP>
<TD WIDTH=40%><FONT FACE="Times New Roman, Times, Serif" SIZE=2></FONT></TD>
<TD WIDTH=10%><FONT FACE="Times New Roman, Times, Serif" SIZE=2></FONT></TD>
<TD WIDTH=50%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Compugen Ltd.<BR>(Registrant)<BR><BR>
<BR>By: /s/ Ronit Lerner<BR>&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;<BR>
Ronit Lerner<BR>Chief Financial Officer<BR>Date: April 29, 2008</FONT></TD>
</TR>
</TABLE>
<BR>
<p align=center>
<font size=2></font></p>
<HR SIZE="1" NOSHADE  STYLE="margin-top: -2px">
<HR SIZE="4" NOSHADE  STYLE="margin-top: -10px">
</body>
</html>







</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99
<SEQUENCE>2
<FILENAME>exhibit_1.htm
<TEXT>
<HTML>
<HEAD>
     <!-- Created by EDGAR Ease Plus (EDGAR Ease+) -->
     <!-- Project:        F:\EDGAR Filing\Compugen Ltd\85158\a85158.eep                    -->
     <!-- Control Number: 85158                                                            -->
     <!-- Rev Number:     1                                                                -->
     <!-- Client Name:    Compugen Ltd                                                     -->
     <!-- Project Name:   6-K                                                              -->
     <!-- Firm Name:      Zadok-Keinan Ltd                                                 -->
     <TITLE>6-K</TITLE>
</HEAD>
<BODY>
<!-- MARKER FORMAT-SHEET="Scotch Rule Top-TNR" FSL="Workstation" -->
<HR ALIGN=LEFT WIDTH=100% SIZE=4 NOSHADE STYLE="margin-top: -5px">
<HR ALIGN=LEFT WIDTH=100% SIZE=1 NOSHADE STYLE="margin-top: -10px">




<!-- MARKER FORMAT-SHEET="Head Major Left Bold-TNR" FSL="Workstation" -->
<H1 ALIGN="Right"><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><U>Exhibit 1</U> </FONT> </H1>

<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Workstation" -->
<P ALIGN="Center"><FONT FACE="Times New Roman, Times, Serif" SIZE=2><IMG SRC="compugen.jpg"> </FONT></P>

<!-- MARKER FORMAT-SHEET="Head Sub 2 Left-TNR" FSL="Workstation" -->
<P ALIGN="Center"><FONT FACE="Times New Roman, Times, Serif" SIZE="4"><B>Compugen
Announces Discovery of Blood Based Biomarker for<BR> Diagnosis of Lung Cancer</B> </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Workstation" -->
<P ALIGN="Center"><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B>Peptide discovered using Compugen&#146;s
immunoassay diagnostics discovery platform</B> </FONT> </P>

<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Workstation" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2><B>Tel Aviv, Israel &#150; April 29
2008</B> &#150; Compugen Ltd. (NASDAQ: CGEN) announced today the discovery and
experimental verification of CGEN-438, a potential blood based biomarker for lung cancer.
CGEN-438 is novel splice variant peptide of delta-like protein 3 precursor (DLL3).
Importantly, the Compugen discovered biomarker is a peptide that is secreted from the cell
into the bloodstream, whereas the previously known DLL3 is a protein located on the cell
membrane. Initial clinical evidence indicates that the Compugen discovered molecule could
potentially serve as both a serum biomarker for the diagnosis of small cell lung cancer
and as a component in a biomarker combination for the diagnosis of non-small cell lung
cancer patients. </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Workstation" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Using a test developed by Compugen to
detect CGEN-438 in serum, the blood levels of the peptide were measured in about 40 lung
cancer patients&#146; and healthy individuals. CGEN-438 concentrations detected in serum
samples of small cell lung cancer patients were higher than those detected in controls,
demonstrating its potential to become a diagnostic biomarker for small cell lung cancer.
It was also evident that CGEN-438 is expressed to a large extent in certain non-small cell
lung cancer serum samples and therefore may be used in a biomarker combination test for
the diagnosis of non-small cell lung cancer as well. A patent application covering this
biomarker has been filed by Compugen. </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Workstation" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Lung <U>cancer</U> is responsible for
the largest number of cancer deaths in both men and women throughout the world and it is
associated with very high mortality rates. However, if diagnosed at a very early stage,
the survival rate for lung cancer patients is high, with approximately one-half surviving
for five years or longer, and there is a significant unmet medical need for such early
detection of the condition. Therefore, a non-invasive screening test for lung cancer with
high sensitivity and specificity would provide both a significant medical contribution and
a substantial commercial opportunity. </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Workstation" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Similar to the recently announced
CGEN-144, CGEN-438 is one of a group of putative cancer and cardiovascular biomarkers
which was initially predicted in silico utilizing Compugen&#146;s immunoassay
computational discovery platform, and then further validated experimentally. </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Workstation" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&#147;We are very pleased by the
continuing successful validation of molecules with significant commercial potential from
the initial group of biomarkers identified by our immunoassay diagnostics discovery
platform,&#148; stated Anat Cohen-Dayag, Ph.D., Compugen&#146;s Vice President of
Diagnostic Biomarkers and Drug Targets. &#147;In this particular case, although the
peptide is a splice variant of DLL3 protein, it shares no sequence similarity to DLL3,
thus further demonstrating the unique predictive power of this specific platform and of
our in silico prediction and selection discovery capability in general. We look forward
to further use of this platform both in our own discovery activities and in collaboration
with partners&#148;, Dr. Cohen-Dayag concluded.  </FONT></P>

<p align=center>
<font size=2>2</font></p>
<HR SIZE="1" NOSHADE  STYLE="margin-top: -2px">
<HR SIZE="4" NOSHADE  STYLE="margin-top: -10px">
<page>

<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Workstation" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2><B>About CGEN-438 and its previously
known form &#150; DLL3</B><BR>CGEN-438 is a novel peptide splice variant of the DLL3 membrane
protein, both are derived from a gene that was cloned and sequenced within the past ten
years. Recent findings suggest that mutations in the gene and over expression of the
membrane protein are associated with cancer. The previously known DLL3 is a single-pass
type I membrane protein, whereas the Compugen discovered splice variant &#150; CGEN-438
&#150; is a secreted peptide having no sequence similarity to the previously known
protein. As a molecule that can be found in the bloodstream, CGEN-438 has the potential
to serve as a biomarker for serum-based immunoassay tests as opposed to its membrane
variant form, DLL3.  </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Workstation" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2><B>About Compugen</B><BR>Compugen&#146;s
mission is to be the world leader in the discovery and licensing of product candidates to
the drug and diagnostic industries under milestone and revenue sharing agreements. The
Company&#146;s increasing inventory of powerful and proprietary discovery platforms is
enabling the predictive discovery &#150; field after field &#150; of numerous therapeutic
and diagnostic product candidates. These discovery platforms are based on the Company&#146;s
decade-long focus on the predictive understanding of important biological phenomena at
the molecular level. Compugen&#146;s current collaborations include Biosite, Medarex,
Inc., Merck &amp; Co., Inc., Ortho-Clinical Diagnostics (a Johnson &amp; Johnson
company), Roche, Siemens Healthcare Diagnostics, Inc., and Teva Pharmaceutical
Industries. In 2002, Compugen established an affiliate &#150; Evogene Ltd. (TASE:
EVGN.TA) &#150; to utilize the Company&#146;s in-silico predictive discovery capabilities
in the agricultural biotechnology field. For additional information, please visit Compugen&#146;s
corporate Website at <U>www.cgen.com</U> and Evogene&#146;s corporate Website at <U>www.evogene.com</U>.  </FONT></P>



<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Workstation" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>This press release may contain
&#147;forward-looking statements&#148; within the meaning of the Private Securities
Litigation Reform Act of 1995. These statements include words such as &#147;may&#148;,
&#147;expects&#148;, &#147;anticipates&#148;, &#147;believes&#148;, and
&#147;intends&#148;, and describe opinions about future events. These forward-looking
statements involve known and unknown risks and uncertainties that may cause the actual
results, performance or achievements of Compugen to be materially different from any
future results, performance or achievements expressed or implied by such forward-looking
statements. Some of these risks are: changes in relationships with collaborators; the
impact of competitive products and technological changes; risks relating to the
development of new products; and the ability to implement technological improvements.
These and other factors are identified and more fully explained under the heading
&#147;Risk Factors&#148; in Compugen&#146;s annual reports filed with the Securities and
Exchange Commission. </FONT></P>

<!-- MARKER FORMAT-SHEET="Head Left-TNR" FSL="Workstation" -->
<P ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Company contact:<BR> Dikla Czaczkes Axselbard <BR>Acting Chief Financial
Officer<BR> Compugen Ltd.<BR> Email: dikla@cgen.com <BR>Tel: +972-54-530-4469 </FONT></P>

<p align=center>
<font size=2>3</font></p>
<HR SIZE="1" NOSHADE  STYLE="margin-top: -2px">
<HR SIZE="4" NOSHADE  STYLE="margin-top: -10px">

</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>compugen.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 compugen.jpg
M_]C_X``02D9)1@`!``$`E@"6``#__@`?3$5!1"!496-H;F]L;V=I97,@26YC
M+B!6,2XP,0#_VP"$``0"`P,#`@0#`P,$!`0$!@H&!@4%!@P)"0<*#PT/#PX-
M#@X0$A<4$!$6$0X.%!P5%A@9&AL:$!0='QT:'Q<:&AD!!`0$!@4&#`8&#!D1
M#A$9&1D9&1D9&1D9&1D9&1D9&1D9&1D9&1D9&1D9&1D9&1D9&1D9&1D9&1D9
M&1D9&1D9&?_$`:(```$%`0$!`0$!```````````!`@,$!08'"`D*"P$``P$!
M`0$!`0$!`0````````$"`P0%!@<("0H+$``"`0,#`@0#!04$!````7T!`@,`
M!!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I
M*C0U-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H.$A8:'
MB(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7
MV-G:X>+CY.7FY^CIZO'R\_3U]O?X^?H1``(!`@0$`P0'!00$``$"=P`!`@,1
M!`4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D:)B<H
M*2HU-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H*#A(6&
MAXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76
MU]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_``!$(`&L!``,!$0`"$0$#$0'_V@`,
M`P$``A$#$0`_`/OZ@`H`*`"@`H`0G`H`H76NZ-:W#P7&K6$,L9PT<EPBLI]P
M3Q5*$FKI`1_\))X?_P"@YIG_`(%1_P"-/V4^S`/^$D\/_P#0<TS_`,"H_P#&
MCV4^S`JZQXW\&Z19F[U7Q;H5A;@X,UU?Q1IGTRS`54,/5F[1BW\@-FQN;>\L
MXKNTFCF@G021RQME74C(((Z@BLFK.P$M`!0`4`%`!0`4`%`!0`4`%`!0`4`%
M`!0`4`%`!0`4`%`!0`4`%`!0`4`%`$5U,(;=Y=COL4MLC7+-@=`.YI;@>5:E
M\5?%LC3VR?`OQM/;MN0/YEO&77IG'F97(_&O2C@:>C]M'\?\A'FMQX7\#SSO
M/<?L;7\TLK%WEE@LV=V/4DF3))]37I1KXB*M'%V7J_\`(FR[#/\`A$O`(_YL
MPNA_VZV7_P`73^LXG_H,_&0:=C'\9>%]$.ANG@_]C?3$U-B`DFKPVOD1CN2L
M;[F/L"OUK6CB*O-^^Q;MY-W_`!#;9'3?LQ?"`:K<7&M_$?X)?#CPZEI*GV"W
ML-'*W#NI#>:6:9U"@XP,9)R>,<\V99BX6AAZ\Y7WN]/0<;]3Z810@PHP!7SY
M0M`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`8'Q
M`\;>$O`^F0:CXO\`$.GZ):7,OD137LPC5Y,%MHSU.%)_"M:.'JUI<M*+;\@/
M!/%/C#X?ZUXAN]33]KZ]TN.X<LECIUS91P6Z]E0&(G`]6))[FO;HX:O3@H_5
M;^;YO\R?F4/[<\`?]'HZ]_X'6/\`\9K3V5?_`*`U]TO\Q?,/[<\`?]'HZ[_X
M'6/_`,9I^RK_`/0&ONE_F'S/./&?Q,\$ZC'J'AZ_^,'QKUG36<PO);P6`@NT
M!ZJ3M8H?<#(]C7?1P-56J*C33\W*Z_&Q+DC`^'GA#X(^-_'&F>$=+UOXM+=:
MO-Y*M)#8QH@P2Q+*Q*C`/(!(K?$XC&8>FZLHPLO\0HI-VU/T%T6PL]*TFUTS
M3[:.VM+*);>"",86.-0%50/0``5\))N3YI;FVQ:H`*`"@`H`*`"@`H`*`"@`
MH`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`/2@#@?BBGQ-EUV"/PCX4\#:OI
MJ0AC+X@U&>"9)22&"HEO(-NW;SG)R>..>O#>P2;JRDGY+_@H3OT.:^R_'3_H
MFOPB_P#!S=?_`"%73S83_GY/[E_\D+W@^R_'3_HFWPB_\'-U_P#(5'-A/^?D
M_N7_`,D'O&'\2+/X]_\`"#:B]OH'PC\*M"BS-K(U69Q:1HP:1B)+$K@HK*2>
M@;/:MJ$L$JBYI3EY66O_`),+WCR#^T/C=_T7'X*_^#2#_P"0:];V6#_Y\U/N
M?_R1/O\`D=!\*O$GQ*T3XA:7JGC#XQ_""]T&WD)O8+35H1*8RI!*8LT.1UQN
M&<=:Y\70P\Z3C1HU%+I=:?FQKF3U/KFSGAN;6.XMI4EAF4/')&P974C(((Z@
MBOE[6T9H2T`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`
M%`!0`4`<Y\2_!6B>.="CTG7/MR0PS+/')8WDMK*C@$</&P.""00>#GZ5M0Q$
MZ$N:'XI/\PL>#>/O"/PJ\(>)'T;4=$^--W(B+(MQI<FJ7D$BGNLD3,/J#@CT
MKV:%?$UH\T907KRI_B0TD8OD?!K_`*%GX_?^`>MUM;%_S4_O@+0;+:_!:2)X
MI?"OQ[DCD4J\<ECK3*RD8((/!!'8TU]<6JG3^^`:'"^.O#GPPLKR`>#O@-X_
MUFV=/WOVVQU.TDB8'C&8B&!'H<BNVC5Q4D_:UXQ]'%_J)I=$8?\`8^@C_FU_
MQG_WWJ/_`,9K?FJK_F*C_P"2_P"8M/Y3U7X(?&+Q!X"L[3PW#\"O']MX<2;Y
MOW%[=R6:'KY2O$/E!YV`],X["O+QF6PK-U/;Q<O5*_XE*36ECZSL+B.ZLXKF
M$L8YD612R%3@C(R#@CZ'FOF;6=C0FH`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*
M`"@`H`*`"@`H`*`"@`H`*`"@`H`K:M%=2:9<16%R+:Y>-EBF9-XC<CY6*]\'
M'%-63NPN>*B7XWQ_)-\9/ADLB?*X_LUAAAUX\[CFO7_V+_GU/[_^`(//^-?_
M`$67X9?^"YO_`(]1_L7_`#ZG]_\`P`#S_C7_`-%E^&7_`(+F_P#CU'^Q?\^I
M_?\`\`#PKXMZ-K_A?Q0W_"0?M-W5C-JI>\2VTJ;4YH(P6Y"[)VV#).%)X'3B
MO9PE2E4A:EAKI=^6_P"*,Y:=3EQJ!_Z.I\0?]^]8_P#CE=7*MOJJ_P#)?\B;
MK^8^J/V%]2>_^$NI0-\09_&RZ?K$L"ZC<0SI)$&BAE\IC,2[X,I8'.`'"C[M
M?,YQ!0KZ4^2Z6FGZ&L=M#VBO**"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*
M`"@`H`*`"@`H`*`"@`H`*`,#XC:Y?^'_``XU[I?AC4?$5T9%C6PL&17(/5BS
MD``#W]*UH4XU)\LI**[L-CY]F\(^#I9GFE_8TE>21B[NZ6)+$G))._DYKWE7
MK15HXS3UD3\AO_"&^"_^C,&_[]V/_P`73^LU_P#H,_&0QDOA+P-"FZ;]C58E
MZ;I!8*/S+T_K%?IC/QD!POB/POXO'B"[;PI^S-\.[#1V8?9H+ZW@DG"@#)=D
MN%7).>`.!CDUV4Z]+D7ML3-R\F[?*Z);ET12_P"$7^*3$)'^SI\,7=ONHE@A
M+'T`%U5>WPJU^L3^]_Y"][L?7_P.\*+X.^&VGZ3)I&B:7?.OVB^@T2V,%K]H
M?ERBEF/H,DG./PKY7%U_;57*[:Z7U=C0ZZN8`H`*`"@`H`*`"@`H`*`"@`H`
M*`"@`H`*`"@`H`*`"@`H`*`"@`Z4;`<C\0OBA\/O`MU%;>+O%^E:1-.,I%<S
M`.1Z[1R!]:Z*&#KXC^%%L+I'#>-/CO\`"+6-$>PTGXWZ7H$TA&Z^LQ'),B^B
M"5&0'IR5;^H[J>4XN$KRHM^7_#"YD>>#Q/\`#8#_`)/-\6_^!-C_`/(E=WU;
M$_\`0)'[I?\`R1%O,/\`A)_AM_T>;XM_\";'_P"1*/JV)_Z!(_=+_P"2#YG&
M>*/B]X7TO57M--^.7QHUN*/@W=G'IRQ,?]DO;@L/?&*ZZ.759J\J-./D^;_Y
M(3=NIQWCOQI\./&L<$7BWQK\:]8BM26BBNFTTHC'N%$0&??&:Z\/A<3A[NE"
MFG_V]^K%==V7_A#\'OAQ\2=66U\,:?\`%EK8-MFU*XCTR.V@]<N8N3[+DU&+
MS'$82/[QT[]O>O\`F-03V/J3]G_]GCP%\)]2GU?2Q>ZMK$V574M5,;201_W(
MA&B*@/<XW'N<8`^;QV;5\8E&5E%=%_P6V7&*B>MUYA04`%`!0`4`%`!0`4`%
M`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`A(%`'%_$K4/BG;ZI!#X!\-^%=0M/
M+W37&M:O-;-OR?E5(X).``#DGOC'&:Z</'#M-UI->B3_`#:$[]#D9F^/LMPT
M\WPY^%$DKX#2/KET6..F2;.NI?4EHIS^Y?\`R0O>&_\`%^O^B;_";_P=W7_R
M'1?!?SS^Y?\`R0>\8/CCQI\2_!T=N?%>@_`_0C>[UMCJ/B.XB$I4#=MS:#=C
M<N<>H]:WH8>A7=J3J.V]HK_,/>/&;[Q)\5KJ\DN#^T+\(;<R,6\FUUB*.)/9
M5^RD@#W)/J2>:]F-#"Q5OJ]3YI__`"1+OW+'AMOC9X@UN#1M`^._PUU34;G)
MBM+/5HY)'P,G"BSST!J:GU*C'FJ4)I>:?_R0*_1GT%\"_AAXZTGR]5^)OCN3
M7+W!QI5I#$EG$3W9Q&KRGZ[5Y^Z<`UX.-QE&?NX:'*N[>O\`DBXIVU/6K6V@
MMH1%;PQQ(O(6-0H_(5YCUW&2CB@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`
M"@`H`*`"@`H`*`"@`H`1NG%)@?)_B"+X-/XAU%[SPA\;FN6O)FF:"'4S&9#(
MVXIM?;MSG&.,8QQ7TE*>*4$HSIVMUY;_`(DZ%3R/@E_T)WQT_P"_.J__`!=:
M<^+_`)Z?WP#0/(^"7_0G?'3_`+\ZK_\`%T<^+_GI_?`-#B_B78^$+C5[5?"W
MP3^(?B*RBA):;7+C589(9&;YE12&^4A4.0>2/:NO#3JI-U:T(ORY61*VUC`M
MM!@N+J&V@_9GU\RW$BQ1A]3U)%+,0HRQ0!1DCDG`K>5?E3?UE?='_,5E_*?9
MWP(^$WA+X;:0\NBZ%;V.J7\:?;I4N)+@[@.4223YM@.<#C/7%?)8S'U<4_WC
MNEMT_!&J26QC?'']H?P!\,]3.BWDMYJ^MJ`7TW2T5V@!&0978A$[<9+8.0I%
M;8+*<1BES15H]WH$I*)YC9?MKZ,UV%NOA]J:6X.&:"_BDD`]E(49^K#ZUZ4N
M&JJ6DU^)'M$?0/PH\>>'?B)X'MO%7AF[>:RG)1TF3RY;>1?OQR*?NLIZ]0>"
M"003X6(PU3#5'2J*S1HFF>4_%']K/X=^%M:GT?0[;4/%%U:DI+/8;$M$<'!3
MSG/SD>J*R]LY!%>GALAQ-:*G*T4^^_W$N:1SF@?MI^&);Y$USP3K.GVC'#7%
MI.ET4']XIA20/]G)]`:Z)\-UDO<FF^VQ*J(]N\8?$SPQH7P:G^)L=P^J:%%:
MK=Q26&TM<HQ`4)N*C))`P2*\:CA*E2NL/:TKVU+NDKGE&@?MA_#[4]=L]-D\
M/>)-/2ZE$;WEZMJD-NO\4CD3$A5&2<`GC@$UZE3A_$0@Y\R?DK_Y$JHC)U;]
MM/PO%K+1Z7X(UN]TU7P+N6:."61<_>6)LD9Z@,5/J%/36'#=9QO*:3["]HC>
M^('[6_P]T/2].FT&TU#Q!>:C;)=&UA"PBT5OX)G;(63((VJ&(QS@$$X8?(,1
M4DU)J*6GKZ>0W-+8Z;]F[X]Z!\7+R^TJWTF\T?5[",3O:7#K(DD1.W<CKUP>
M""`1D=:YLPRNI@DI-W3Z^8XR3.0\0?MA^`=*\0ZEI!\,>*KIM-O)[)I[>.V,
M<IBD:,NF9@2I*$@D#((KKH\/8BI",^9*ZOKY_(7.BGXJ_;+\&V1MDT#PMK&K
M.\*2W!EDCMT@=E#&+/S%W4DJQ`VY'#-SBZ7#M>=^>2B)U$MCT_X"?&;PS\4_
M"M_JNE0W5A<Z.0+^PNPOF0`J2K@J2&1@K;6']U@0""!YN.R^K@YJ$];[,J,D
MU='F,_[:?P^C\S;X0\7R",L`5BM?GP<<9G[UZ2X;Q#^U'[W_`)"]HCM?C'^T
M/X8^&RZ"NMZ!K]Q/KUB+](+1("UNAQ\LFZ11NR2.,C@\UQ8/*JN*YN1I<KMK
M_P`,-R2+OP!^.GAWXLW>L1:+HFM:9'HD44L\^IK"J'>7X!21N0$R<XX(J<=E
ME3!<O.T[]F.,D]CS_P`<?MD>"=-UA[3PKH.H^)+>)BIU!95MK>7WB+`LZ_[6
MT`]02.:[J'#U><5*HU&_3J2ZB6Q(_P"V7\/8]*L;@^'/$TES<*_VBUAB@)M6
M4@`%FD4,&SE2N>`<[2,4EP[B>9KF6GGO^'02J(]*^`WQ@T/XJ:!JFM:5I6J:
M39:3*(99-4$2!CLWD@H[#`&,DD5Y^-R^>#FH2:;?8M-,\Y^(7[87P_T35)K#
MPWI>I>)?L[%6O82MO:,1P=CO\SC/\07:1R&->AA^'L14CS3:CY:W^Y$NHEL0
M>`?VQO!FK:[;Z?XD\/:EX>ANI%B2^,J7$$9/`\PKAE!.!D*0,\X'-.OP]7IQ
M<H24K=-F$9INQZ3^T%\:/#GPBL](GUO3]3U$ZU)(D$6FK$S!44,SG>ZC;\RC
M@GEA7GX'+JF,<E3:5NY4I*)P>C?MA?#>\L]1NKK1O$FG)I\"RHD\,#27<C-M
M6&)4E)+GDDG"J`2S`<UVU.'\3!Q2:=_P\WH)31F^$/VR/#&J>++/2]6\(:II
M-E>W"6ZW_P!H281%V"JTB``A<D9*EL=<$9K2KP]6A3<XS3:5[>A*J*]CZ67I
M7SYH+0!Y)\21X^T[Q;<-#\:_"WARPNV,EG8:GIL1E1``&^9I5+@-GG'<"O1H
M/#N%I4G)]T_^`)W,'^T?'O\`T<EX!_\`!=;_`/QZMO\`9_\`GQ+[W_D+7N']
MH^/?^CDO`/\`X+K?_P"/4?[/_P`^)?>_\@U[G"?'FPUC4?#T.N^)?VEK)8-%
MWX7PO$T<S"5HU.Z."XS(`57'!*@L>A-=V!J4XSY*6'U?\VVGJM!-/N6_V'M+
MTO4_B5J6MV'Q<\5^+UT:S$;66HI=PPQ/,Q"N1+(RN=L;@#'&<^E3G,Y1I1A*
MBH7=[JW3T007F>^_''Q6?`WPA\2>+8U#3:1ITUQ!&>DDP4B-3]7*C\:\3!T/
M;UX4N[2*;LC\U]!TW4O%?C2RTE[R674_$6HQP2WA.9'EFD`>3GOR3^`K]$J3
MCAZ3DEI%;',E=ZGUM^T/\`_A[JVNZ1::/XQ\+>!(])L1;-8ND2R3C/RN^75F
M.`1N;)/.2:^3P&:UJ:DYQ<[NYM*%SB?B'H[_``1_9?U71?#WCJW\0#QOJZV_
MVS3\*D4:Q8F4%6;YB$`//3BNS#S688V,YPMR+9_@*W)$\O\`V5/!%EX[^.>B
M^'M1MQ)I<(>[O(1PKQ1KD(<=BQ4''K7JYKB98?#2G%ZZ)$4XZZE#]H:VT.Q^
M.OBNQ\-645EI5I?F"WMX?N(415?;[&0.?QJ\M<WA8.H[NWZZ"DM6=SXHUB[T
MO_@G_P"%O#\DA'_"1>))F2)CS]DA>28L/]GSDB'_``,>M<-*G&>:3FOLQ_%V
M7Y7*?P&#^R+X(TGQ]\<+72?$%H+K1["RGU&\MRQ42*FU5!(YQOD0X]JWS;$S
MPN'YJ;M)NR_,5-)O4\WU6YL)M0OKS3(_+T^2>:6T3.[;`78QC/?Y-M>E34N5
M*>^E_4E^1ZE^TAX*\.>!/"/P\TW3]/6'7=1TDZAJMSO8F9FVXR"<#!+`8`X%
M>7EN)J8BI5G)^ZG9%SBDE8Z?]@P+HEWX]^(,VU8O#NAL$9NF\[I/Y(!7-GKY
M_9X=;M_\`JFK:G@-M!>7IAM+7#7U](D$.[D&61@JY_X$PS7O7C!7Z+]#+<]O
M_;?\#>#?AWK/@KP[X5T^.UN_[,GEU*0.6><AH4B>3)ZDB?!&.C>V/&R3$UL1
M&I.J[JZM^-_T+J*UBA^S)J]WX8^&/Q>\3VS*/LN@PVL8+8W3RO*L8_G3S2"J
MUJ%)]9/[M`@[)L\V^&VAMKOCSP_X<B`;[??V]K@]P74'/X9KT\35]E2G4?1,
MF.YZ9^W=K::K^T;J%E`P-OH5I!8(`>`0N]A^!?'X5YN1T>3"*3ZMLJIN,T:_
MN/"'[$NI/:2-#=?$'7C8R.G!-I%'^\&?1@FP^SFE."K9BD]J<;_,<;J&AS_[
M+?@BS^(/QST;P[JD32:6GF7E[$I(\V*,9$9(Y`9BH..V1WKIS3%2PV&E.&CV
M1--)LK?M(6'A_2OCSXITGPK8QV6E6%VMM%;Q$[4=8T$F,_\`33?59;*<L+"5
M1W;%/?0['7]5OO"?[#7A?0;626VE\?:E=ZA=E3C?:I(50`C^%T2$GV)%<=.G
M&MF4ZC^PDEZV_1W+=XPL>?\`PBOKO2/%G]LVGP_;QG]BC(^Q-8374,+M]UW6
M)6]&P&X//I7?C(J=/D=3DOUNE?[R87WL0^,-#\6ZQK>I:I!\,_$6F1WTKS+8
MV>@7@A@W<[$!CX7T%.E5HTXJ+JIVZN2_S#E=[V/0OVUM4O9O&?A'PW>2L[>'
M/#-M'*C@ADN)OFE!S_L1P?K7GY+32IU*J^U+\%_PXZNZ*GPG\&>&)?V9/B3\
M1O$VG_:KC3(QIVCLSLHBN7"JC#'4F66)><]#6F+Q558RCAZ3M?5_UZ!&*Y;L
M\_\`ASH[^(/B/X;T"/KJ6JVMN3_LF5=Y_P"^0U=^*J*G0G-]$R(J[2/U+7I7
MYJ=0M`''_&'PEX<\0>'WU#5OAWHWC.^TR-GLK'4+>%F9CC*H\H(3./H<"NG#
M8BK1E:G4<$][-_H#/&AX:T[_`*,KT3\]+_PKU_;S_P"@Q_\`DQ.O87_A&M._
MZ,KT3\]+_P`*7UB?_08__)PN^PJ>&[!&#+^Q;HJD="K:6"/TH]O/_H,?_DPM
M>QT'[)6A^-]$\3>)!XF^&WA[PCI]TL+63Z3:6\$DVUY/DF,1(8JK#!Z<MCK7
M/F=2C.,/9U')K>[;^ZXXJW0])^-O@Y/'_P`*/$'@YI_LS:O9/!%.1D12]8W(
M[@.%)'?%<&$Q#PU:-9=&4UI8^!C\//C!\.?'=CJ?_""ZP=1T:[2YM[BSLVN[
M=W4\$&/.5/O@\U]O]<P>*I./.DFMF[,YU!QU1LM\*/C9\9?B'=^(=:\,7%G=
MZFZ^=J.L0?9H($`VJ%0_/M4#A0.>>><UE''X/`4E3IRNET75^H<LI.[/H3XR
M?LZK<?LSZ)X#\%21F_\`"TGVN!IP(Q?2MN\XMCA6<NQ'8'`KP,%F[CBY5Z^T
MM'Y=ON-91TLCYE\(:)\;?AGXQ;4M#\&^)M.U4PO;&1-+:Y0HW7E0R]@0<\$"
MOI:U7!8NGRSFFO6QDE*.QT'PE_9N^)?C?7DN/$>GWGAW2YI3)=WVHX%S)DY;
M9'G.XY/+8`Z^U<V*SC#X>/+2?,TK*VPU3;>IWW[;'PZ\67VL^#O"OP_\"ZK>
M^'O"VDM!";*)3'&SLHVY+#D+$F?K7%DN,I152K7FE*3Z_/\`S+G'30J?LS_#
MWXA^"OAA\4_$5SX/U>UU^^TI-,T>R:-1.[E9"73#8QNECSR/]559EC,/7KT:
M:FN5.[?3I_D*$6DSR?PK\"_BA<Z_H^DWGP^UVQL+B]MK6>YDB39;P-*B22'#
M=%0LWX5ZE?-,-&$I1J)NSMZVT(4'<](_;*\"_$OQ?^T%J.H:'X"UR]TFRM+>
MRM9X(T,;A5+,5RPXR^.G\-<&3XO#4,*HSFDVVV7.+>PL6BZ[\,/V%O%">(-(
MN])U?Q7J\=B+>Y`5UCRHR<$\%4D_.I=2&+S*'LW>,4%N6.IXA\/-!\1>(_&%
MIIGA."276$)NK58W"L&B^<%2>,\#&>M>WB:M.E3<JNW^>AE%.^AUWB'PI\<?
MB9X_>^USPEXDO]:G5(&FO+(VT,*+D!0Q`15!)/&>23R37'3Q&"PE/EIS2COH
M[LMQDV>_>*/@!K7AG]C+4_!OAY1J?B6]O8=7U%83C[7(K)F*//94C4*#U*YZ
ML:\.GFL*N81K5-(I67EY_>S3EM&R/GSX6?#?XPOX_P!/D\,>$M>TG5;*X$D>
MH7MF88K5A_$S2#:1@G@;L]*][%8W!^Q:J333Z)ZLRC%WT#Q-\)/C1=^(M3O;
M[P+XCU2[GN9'FOC$G^E-N/[SENC8!'MBG1S'!1A%1FHJVVN@W"5]3W_Q_P#`
MZ^UC]D?P;X9MYK&P\4Z#&M^MM>2+%YK2`^="2?NM\PYZ;D&?4?/T,U5/'5*L
MM82T_P`F6X^[8\>^&7P8^/-AXL2Z\-6DWARY3,,FJIJ$(2&-OO9*ELC'.,9X
MXP>:]C$9G@)T[5'S>5B(PDCQQVDO$=K&>2[ENW/D3L69KAG;Y7)/)+$AN>>>
M>:]=6@O>5DOP\B=V?:?[4WP-UO7?@AX,TWP?;+<WW@FSCM%T_<%,\(B1"$)X
MW#8#@]>:^.RS,X4L3.=9Z3=[]G>YM.-T>!_"R[^._P`,GUK3O"G@KQ%:3:W&
MD5R9-%ED9"FX*R/C:&&]N<D<^U>YBHX#%<LJLU[M^IG%2BK(]+_9N^$GQRUO
MQC8ZQX]\8^/-%T*RD6>2TN_$EX9[T@Y";!,0JYQG/;@#FO.S',,'"FX4(1<G
MUY59?@7%2W9Q/[17P]^*WBSXY>)]?M/AYXAN;2XO"EO,L28>)`$4C+="%XKN
MR[&86AAH0=1)_P"9,XML[+Q5\._'^E_L-^'/`^E>$]7NM6UC6/[1U6QAC4O`
M@=YE63YL<2+#CD_=KAHXRA+,I5I22BE9/Y6_S&XM1L9'['/PB\=Z?^T-HVM>
M*?!^J:1IVCP7%V)[R-0CR[/*1!ACS^]9A_N5OF^84)85TZ,TV[;??^@H1:>I
M]OKT%?&HV8M,`([4`)M%+E2'<,#WHL@N&![T607`#%%A"TP$P/>E8=PP*+"%
MQQBG:P"8^HI6``,4]@`CBE8`VCWHL`;1[TPV`J/<4K`>&_ML?#7QQ\3=$T'2
M?"45DT%E<R7-R;JX\O)V[4`&.>I->QDV-HX2<IU;[6T(G&ZLCD?V//@%XT^'
MWQ6N/$WB^+3T@BT]X+7[+<^8WFNRYR,=-H-=F;9M1Q-%4Z5]];BA#E/J#;]:
M^;L:+0,4P#;]:`#;]:5@/G_]M3X":C\5Y])U_P`/36/]JZ5"]LUK?#"3Q%@P
MVO@[6!SUX(/;'/N9/FBP7-3J7Y7V)G&^QX%HO[.GQ\TBPU#2='TU],L=73R;
M^"RU988;M,$;954C>N"00>H)!X)%>[/-\#-J<W=K:ZO8S49H]8_9K_98O/#G
MC"R\6_$"]M+B?2Y1/9Z5:9>,2C[LDCG[VWJ%`QD`YX%>5F.>*M3=&@K)[ME0
MIVU9]2X`KYNQH&*+`M```HL`;?<T6`,"BP`%QZT6`6GL`4`%`!0`4`%`!0`4
M`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`'
"_]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
